Filing Flows › Integra Lifesciences Holdings (IART) › Capital expenditures
Integra Lifesciences Holdings (IART) capital expenditures by quarter
Integra Lifesciences Holdings' capital expenditures were $10.2M in Q3 2026 (third quarter 2026), -17% from Q2 2026. Over the last 6 quarters it ranged from $10.2M (Q3 2026) to $20.1M (Q2 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $10.2M | -17% | -32% |
| Q2 2026 | $12.3M | -17% | -39% |
| Q1 2026 | $14.8M | -14% | — |
| Q4 2025 | $17.2M | +14% | — |
| Q3 2025 | $15.2M | -25% | — |
| Q2 2025 | $20.1M | — | — |
Q3 2026 at a glance
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Integra Lifesciences Holdings' capital expenditures?
Integra Lifesciences Holdings' capital expenditures were $10.2M in Q3 2026 (third quarter 2026), -17% from Q2 2026.
How has Integra Lifesciences Holdings' capital expenditures changed?
Over the last 6 quarters it ranged from $10.2M (Q3 2026) to $20.1M (Q2 2025).
Q3 2026 results → · How Integra Lifesciences Holdings makes money →